Pharmaceutical patent analyst最新文献

Primary Amoebic Meningoencephalitis (PAM) is a severe and often fatal infection caused by the free-living amoebae Naegleria fowleri. This condition typically results from exposure to contaminated warm freshwater/inadequately treated recreational water/or ablution/nasal irrigation with contaminated water. The management of PAM is hindered by the absence of effective treatment coupled with challenges in early diagnosis. This review explores emerging patents that could be utilized for the treatment, diagnosis of PAM, as well as water treatment. Recent patents from the past five years, along with research and innovations are reviewed and categorized into therapeutic agents, water treatment technologies, and diagnostic methods. It is hoped that collaboration and awareness between pharmaceutical companies, water industries, and academic institutions is essential for advancing effective strategies against this severe central nervous system pathogen.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

The glucokinase enzyme (belongs to the hexokinase family) is present in liver cells and β-cells of the pancreas. Glucokinase acts as a catalyst in the conversion of glucose-6-phosphate from glucose which is rate-limiting step in glucose metabolism. Glucokinase becomes malfunctional or remains inactivated in diabetes. Glucokinase activators are compounds that bind at the allosteric site of the glucokinase enzyme and activate it. This article highlights the patent and recent research papers history with possible SAR from year 2014-2023. The data comprises the discussion of novel chemotypes (GKAs) that are being targeted for drug development and entered into clinical trials. GK activators have attracted massive interest since successful results have been reported from clinical trials data.

Three-dimensional (3D) printing is one of the most flexible technologies for preparing tablets, offering controlled drug release profiles. The current patent describes the preparation of immediate-release 3D-printed tablets of hydrochlorothiazide to improve disintegration and dissolution profile. The patent involves the preparation of drug-loaded filament via hot-melt extrusion and utilizing the same filaments for printing 3D-printed tablets using fused deposition modeling. The tablets were printed with different shapes and sizes by incorporating channels within the tablet spaces, termed as gaplets. The introduction of channels within the tablet design improves the disintegration and dissolution profile of the drug significantly. The morphological characteristic of 3D-printed tablets was studied by using scanning electron microscopy and revealed the presence of gaplets in the tablets.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.